Mary DuCharme

Mary DuCharme

Auto-generated profile, based on publicly available information

Mary DuCharme

Optum , Eden Prairie, MN

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
Justin GatwoodJustin Gatwood
Justin Gatwood
YZYong Zhu
Yong Zhu
ASAndrea Steffens
Andrea Steffens
SGStephanie J Gallagher
Stephanie J Gallagher
MDMary C DuCharme
Mary C DuCharme
NSNikita Stempniewicz
Nikita Stempniewicz
Purpose: Cancer and immunosuppressive medications used for its treatment increase the risk for herpes zoster (HZ) among adults. This study described the incidence of HZ and its complications among United States (US) adults with specific solid tumors and hematological malignancies following initiation of immunosuppressive therapy. Patients and Methods: This retrospective cohort study used administrative claims data from October 2015 to December 2022 and included US adults with ≥ 1 immunosuppressive medication claim, ≥ 12 months continuous enrollment (baseline) prior to the first immunosuppressive medication claim, a cancer diagnosis, and no HZ diagnosis or vaccination in the baseline period. HZ incidence rates (IRs) were calculated as the number of new HZ cases per 1000 person-years at risk, stratified by cancer type and medication class. The proportions of patients with HZ-related complications such as postherpetic neuralgia, herpes zoster ophthalmicus, disseminated HZ, and HZ-related meningoencephalitis were described. A time-dependent Cox proportional hazards regression estimated adjusted hazard ratios, controlling for patient age, sex, race and ethnicity, comorbidities, prior healthcare utilization, insurance type, region, and baseline immunosuppressive medication use. Results: The overall IRs of new HZ cases in patients with a solid tumor or a hematological malignancy were 20.9 (95% confidence interval [CI]: 20.33‒21.52) and 31.1 (95% CI: 29.64‒32.52) per 1,000 person-years, respectively. HZ IR was highest in patients with non-Hodgkin lymphoma (35.4, 95% CI: 33.05‒37.77) or chronic lymphocytic leukemia (35.1, 95% CI: 31.24‒39.24). By medication class, the highest HZ IRs were associated with mycophenolic acid, azathioprine, and oral glucocorticoids. In adjusted analyses, patients were more likely to develop HZ during periods of immunosuppressive medication use versus periods without (adjusted hazards ratio [95% CI]: 3.2 [3.01‒3.39] for solid tumor, 3.2 [2.89‒3.57] for hematological malignancy). Conclusion: HZ incidence among US adults with solid tumors and hematological malignancies following immunosuppressive therapy initiation was high, reinforcing the need to prioritize HZ vaccination in these populations. Plain Language Summary: Why was the study done? Adults with cancer have a higher risk of developing herpes zoster (HZ) compared to the general population, due to both cancer and its treatments. The risk of HZ in adults by cancer type and medication class has not yet been comprehensively examined. What did the researchers do and find? This study estimated HZ incidence among United States adults with cancer following immunosuppressive therapy initiation. This study found that HZ incidence is particularly high in patients with solid tumors or hematological malignancies in the period following immunosuppressive medication initiation. Moreover, patients consistently on immunosuppressive therapy were more likely to develop HZ compared to patients with less consistent use of immunosuppressive medications. We identified mycophenolic acid, azathioprine, and oral glucocorticoids as medications associated with higher rates of HZ incidence. What do these results mean? The findings provide oncologists and hematologists with information about the risk of HZ in patients with different cancer types during periods of immunosuppressive medication use. This may also inform decision makers about the need for HZ vaccination in patients at increased risk for HZ due to both their health condition and treatment. Finally, this may provide guidance to providers by linking the need for HZ prevention with specific classes of medications, irrespective of their connection to cancer therapy.

29 May 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
YKYongJin Kim
YongJin Kim
YZYong Zhu
Yong Zhu
KMKristin J. Moore
Kristin J. Moore
MDMary DuCharme
Mary DuCharme
DJDan James
Dan James
KOKim Ohaegbulam
Kim Ohaegbulam
Introduction Among patients with unresectable stage III non-small cell lung cancer (NSCLC), those whose tumors harbor epidermal growth factor receptor mutations (EGFRm) are associated with comparatively fewer treatment options and worse prognosis. With the recent approval of targeted treatment, characterizing the economic burden and EGFRm testing and provider referral patterns is crucial to understanding the unmet needs of these patients. Methods This was a retrospective analysis of Optum’s Market Clarity Dataset from January 1, 2018 to June 30, 2023. Eligibility criteria included diagnosis with unresectable stage III EGFRm NSCLC and chemoradiotherapy (CRT) initiation (index date) within 90 days. Primary outcomes were per patient per month (PPPM) all-cause and NSCLC-related health care resource utilization (HCRU) and costs, and EGFRm testing and provider referral patterns. Results A total of 144 patients were followed for a median of 15.5 months; 56.3% of patients underwent EGFRm testing before CRT initiation. All-cause and NSCLC-related costs during follow-up were $28,020 and $22,816 PPPM, respectively. Ambulatory utilization was the major driver of this economic burden. Pharmacy costs accounted for $4244 (15.1%) and $3736 (16.4%) of the total all-cause and NSCLC-related costs, respectively. Between diagnosis and CRT initiation, the most common specialties visited were oncology/hematology (seen by 67.4% of patients), radiology (26.4%), pulmonology (22.2%), and cardiology (21.5%). Patients who visited three or more specialties on separate days before CRT initiation had a median time to CRT initiation of 33.0 days versus 22.0 days when patients visited multiple specialties on the same day (suggestive of a multidisciplinary care team, MDT). Conclusion Patients with unresectable stage III EGFRm NSCLC incur substantial economic burden, especially in ambulatory HCRU and costs. With the recent approval of targeted treatment for these patients, reflex EGFRm testing in all early-stage NSCLC at diagnosis is encouraged. Our results also suggest MDT involvement may improve completeness in diagnosis and staging, resulting in acceleration of treatment planning and management.

3 November 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
NSNikita Stempniewicz
Nikita Stempniewicz
ASAndrea Steffens
Andrea Steffens
KKKimvi Kim
Kimvi Kim
MDMary DuCharme
Mary DuCharme
YZYong Zhu
Yong Zhu
DSDavid Singer
David Singer
Background: Recent United States data on incidence, healthcare resource utilization (HRU), and costs for herpes zoster (HZ) in adults with human immunodeficiency virus (HIV) are lacking. Methods: This retrospective cohort study included insured adults during 2015–2022. HZ incidence rates were estimated among HZ-unvaccinated adults with HIV, HIV without other immunocompromising conditions (ICC) (HIV only), and 1,000,000 randomly selected adults with no ICC. Poisson regression was used to estimate adjusted incidence rate ratios (aIRRs) and 95% confidence intervals (CIs). All-cause HRU and costs were compared between propensity score-matched cohorts with HIV and HZ versus HIV without HZ during the first 1, 3, and 12 months after an episode of HZ. Results: The incidence rates of HZ in the HIV (n = 53,700), HIV only (n = 41,544), and no ICC cohorts were 12.0, 10.3, and 5.6 per 1,000 person-years, respectively (HIV vs. no ICC: aIRR 2.05, 95% CI 1.92–2.19; HIV only vs. no ICC: aIRR 1.93, 95% CI 1.79–2.09). Mean all-cause per-patient costs were higher among adults with HIV and HZ during the first month (n = 1,078 and 4,312; cost difference $3,075, 95% CI $1,239–4,911) and the first 3 months (n = 994 and 3,976; $2,980, 95% CI $649–5,310) compared with adults with HIV without HZ. Conclusions: People with HIV are at increased risk of HZ compared to adults without ICC, and the costs associated with HZ among people with HIV are considerable. These findings support the importance of HZ prevention for adults with HIV.